|Articles|July 15, 2002
Blue-light damage is well-established risk in pseudophakia
Like most ophthalmologists, I knew little about the significant body of work in the peer-review literature documenting the harmful effects of visible blue-wavelength light on the retina. Because an effective solution to the problem seems to be on the way, the time has come for us to begin to recognize the implications of blue-light exposure in pseudophakic patients.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Retina experts reflect on how OCT transformed patient care
2
AAO 2025: The ASPIRE phase 2B trial of UBX1325 head-to-head against aflibercept
3
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
4
Redefining glaucoma care: Where innovation meets clinical insight
5















































.png)


